1.59

2.58% 0.04

Regulus Therapeutics Inc (RGLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.55

Offen:

$1.53

24-Stunden-Volumen:

441.41K

Relative Volume:

1.23

Marktkapitalisierung:

$104.15M

Einnahmen:

Nettoeinkommen (Verlust:

$-30.04M

KGV:

-0.9408

EPS:

-1.69

Netto-Cashflow:

$-27.38M

1W Leistung:

+0.63%

1M Leistung:

+13.57%

6M Leistung:

-36.90%

1J Leistung:

+20.45%

1-Tages-Spanne:

$1.5101

$1.60

1-Wochen-Bereich:

$1.50

$1.70

52-Wochen-Spanne:

$1.08

$3.79

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Firmenname

Regulus Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

858-202-6300

Adresse

4224 CAMPUS POINT COURT, SAN DIEGO, CA

Mitarbeiter

Twitter

@regulusrx

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

RGLS's Discussions on Twitter

Vergleichen Sie RGLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RGLS Regulus Therapeutics Inc	1.59	104.15M	0	-30.04M	-27.38M	-1.58
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-02	Eingeleitet	Oppenheimer	Outperform
2024-03-18	Eingeleitet	Leerink Partners	Outperform
2018-03-28	Eingeleitet	B. Riley FBR, Inc.	Neutral
2018-01-05	Eingeleitet	Leerink Partners	Outperform
2017-06-13	Bestätigt	Chardan Capital Markets	Buy
2017-03-06	Bestätigt	Wedbush	Outperform
2017-01-30	Herabstufung	Needham	Buy → Hold
2017-01-30	Herabstufung	Wells Fargo	Outperform → Market Perform
2016-12-07	Bestätigt	Chardan Capital Markets	Buy
2016-11-02	Bestätigt	Needham	Buy
2016-07-25	Bestätigt	Chardan Capital Markets	Buy
2016-06-28	Bestätigt	Chardan Capital Markets	Buy
2016-06-28	Bestätigt	FBR Capital	Outperform
2016-06-28	Bestätigt	Needham	Buy
2016-06-07	Bestätigt	Chardan Capital Markets	Buy
2016-04-13	Eingeleitet	Chardan Capital Markets	Buy
2015-12-04	Eingeleitet	Wells Fargo	Outperform
2015-06-09	Eingeleitet	Guggenheim	Buy
2015-04-21	Fortgesetzt	FBR Capital	Outperform
2014-11-24	Eingeleitet	Deutsche Bank	Buy
2014-08-07	Bestätigt	FBR Capital	Outperform
2013-08-14	Bestätigt	Needham	Buy

Alle ansehen

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

Dec 21, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts - Defense World

Dec 21, 2024

Dec 19, 2024

Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St

Dec 19, 2024

Fmr LLC Has $515,000 Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Dec 19, 2024

Dec 18, 2024

Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017 - BioSpace

Dec 18, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages - MarketBeat

Dec 18, 2024

Dec 17, 2024

The Manufacturers Life Insurance Company Purchases New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Dec 17, 2024

Dec 16, 2024

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - StockTitan

Dec 16, 2024

Dec 12, 2024

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - Longview News-Journal

Dec 12, 2024

Dec 11, 2024

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - The Eastern Progress Online

Dec 11, 2024

Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Dec 11, 2024

Dec 08, 2024

With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns - Yahoo Finance

Dec 08, 2024

Dec 05, 2024

RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Dec 05, 2024

Dec 01, 2024

NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Dec 01, 2024

Nov 29, 2024

Victory Capital Management Inc. Has $626,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Nov 29, 2024

Nov 26, 2024

Regulus Therapeutics Announces Participation at Upcoming Healthc - GuruFocus.com

Nov 26, 2024

Regulus Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences - StockTitan

Nov 26, 2024

Nov 23, 2024

Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80 - MarketBeat

Nov 23, 2024

Nov 21, 2024

Regulus Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 21, 2024

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates - GuruFocus.com

Nov 21, 2024

Nov 16, 2024

Annovis Bio (NYSE:ANVS) versus Regulus Therapeutics (NASDAQ:RGLS) Head-To-Head Contrast - Defense World

Nov 16, 2024

Nov 15, 2024

RA Capital Management's Strategic Reduction in Regulus Therapeutics Holdings - GuruFocus.com

Nov 15, 2024

Biotechnology Value Fund L.P. Increases Stake in Regulus Therape - GuruFocus.com

Nov 15, 2024

What is HC Wainwright’s Estimate for RGLS FY2024 Earnings? - Defense World

Nov 15, 2024

Nov 14, 2024

FY2024 Earnings Forecast for RGLS Issued By HC Wainwright - MarketBeat

Nov 14, 2024

Creative Planning Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Nov 14, 2024

Nov 11, 2024

Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 07, 2024

Regulus: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 07, 2024

Nov 06, 2024

Regulus Therapeutics (RGLS) Stock Price, News & Analysis - MarketBeat

Nov 06, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com

Nov 05, 2024

Oct 30, 2024

HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 30, 2024

Oct 29, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat

Oct 29, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Yahoo Finance

Oct 29, 2024

Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India

Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa

Oct 24, 2024

Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com

Oct 24, 2024

Oct 19, 2024

Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World

Oct 19, 2024

Oct 13, 2024

Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Oct 13, 2024

Oct 08, 2024

HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 08, 2024

RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 08, 2024

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Oct 08, 2024

Oct 04, 2024

Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat

Oct 04, 2024

Oct 03, 2024

Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 03, 2024